Associate Research Fellow, Rare Disease
As a key member of the rare cardiovascular disease discovery biology team, the successful candidate will be responsible for implementing and leading discovery projects from ideation to early clinical development within the Rare Disease Research Unit’s portfolio. Interacting with clinical development and computational geneticists, the candidate will drive the rare cardiovascular disease area strategy, including new target selection, and support biomarker development needs for clinical trials.
- Lead biology research teams working on rare cardiovascular disease programs in the RDRU portfolio which cover a breadth of modalities including AAV gene therapy.
- Develop scientifically rigorous translational research strategies to utilize the most relevant nonclinical in vitro and in vivo models, enabling robust clinical translation.
- Analyze, interpret and report results of nonclinical studies in support of regulatory filings.
- Partner collaboratively across integrated, multi-functional teams encompassing research (including biostatisticians and computational geneticists) and development (clinical, clinical pharmacology, statistics, development operations) and clinical biomarker assay specialists, diagnostics and asset leaders, while fostering a culture of scientific excellence and innovation. Work to build synergy with groups in Pfizer working on non-rare cardiovascular indications.
- Assess state of the art technologies, collaborate closely with computational and systems biologists, and innovate with academic collaborators to expand rare cardiovascular translational research.
QUALIFICATIONSCandidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
- Advanced degree (PhD/MD) with focus on cardiovascular disease biology and a minimum of 8 years’ experience in Cardiovascular/Metabolic drug discovery and development.
- Candidate should possess a sophisticated understanding of modern cardiovascular tissue biology, mouse models of cardiovascular disease and human cardiac genetics, with a documented focus on translational research.
- Demonstrated excellence designing, executing and interpreting studies of cardiovascular disease biomarkers in nonclinical studies that enable their validation for clinical application.
- Ability to drive interactions at the interface between the research unit’s discovery biologists and appropriate partner lines, (eg. Chemistry, AAV vector generation teams, Clinical).
- Significant external scientific influence within the academic community, publication of primary research results in high quality, peer-reviewed journals and national/international scientific reputation
- Direct experience or familiarity with state-of-the-art technologies applicable to cardiovascular disease biomarker analysis such as next-generation sequencing, immunohistochemistry, immunofluorescence, flow cytometry, in situ hybridization, gene expression profiling, and digital image analysis.
- Demonstrated ability to think strategically and creatively while contributing to multiple projects, thrive in a highly collaborative, multi-disciplinary team setting; highly effective verbal and written communication skills.
- Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
- Experience with multiple modalities as therapeutics for cardiovascular disease (e.g. small molecules, biologics and AAV viral vectors).
- Experience with iPSC-derived cardiomyocytes (generation and functional assessments).
- Demonstrated ability to thrive in matrix organizations.
- Experience leveraging genomic and molecular information from cardiovascular disease patient registries
Other Job Details:
Eligible for Relocation Package
Eligible for Employee Referral Bonus
Pfizer requires all U.S. new hires to be fully vaccinated for COVID-19 prior to the first date of employment. As required by applicable law, Pfizer will consider requests for Reasonable Accommodations.
Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider’s name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.
EEO & Employment Eligibility
Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.Research and Development